Co-registered photoacoustic and ultrasound imaging for non-invasive ovarian can

光声和超声共配准成像用于非侵入性卵巢癌检测 与表征 摘要 我们建议开发一种新的经阴道成像设备， 超声技术用于卵巢癌的双模态非侵入性检测和表征 和原位异常。光声技术提供了肿瘤血管生成的光学对比 和肿瘤缺氧，超声（US）分辨率可用于高达3-4 cm的深位病变。的 这种非侵入性成像技术能够对卵巢中的早期血管生成变化以及肿瘤缺氧进行成像， 成像方式将大大提高对有卵巢癌风险的妇女的护理。 从我们对正常、异常和恶性卵巢组织的离体成像中获得的数据， 表明，当恶性肿瘤和 将异常卵巢组织与正常卵巢组织进行比较。我们开发了一个原型- 注册的光声和US系统，这使我们能够验证这一新的假设， 成像设备将改善目前的临床实践，用于早期无创诊断 卵巢癌和卵巢异常，并将指导高危卵巢癌的手术干预 患者 在该提案中，我们将1）开发适合于以下的经阴道光声/US探头和系统： 卵巢的体内双模态非侵入性检测和表征; 2）表征正常， 通过将成像结果与组织病理学进行比较， 微血管密度计数和分布以及平均光吸收; 3）评估 用于预定进行预防性卵巢切除术的患者的体内成像的原型探针; 4） 监测一组高风险的绝经前妇女在月经周期，以确定 功能和形态参数的周期性变化可能与血管生成变化不同 与恶性过程有关。将招募约60名患者进行离体研究。 目标2中的研究，这将使我们能够验证所提出的初始灵敏度和特异性 法目标3的体内研究将招募大约40名患者，这将使我们能够 以评价该技术并验证离体结果。大约20到25岁的绝经前高- 目标4中的体内研究将招募风险患者，这将使我们能够评估 这项新技术在绝经前人群中的应用。 该项目的成功完成将为改善目前的临床 实践：它将提供必要的技术，以提高确定是否存在癌症的能力 并避免大量女性接受手术。

Co-registered photoacoustic and ultrasound imaging for non-invasive ovarian cancer detection and characterization Abstract We propose to develop a new transvaginal imaging device using co-registered photoacoustic and ultrasound technique for dual-modality non-invasive detection and characterization of ovarian cancer and abnormality in situ. The photoacoustic technique provides optical contrast of tumor angiogenesis and tumor hypoxia with ultrasound (US) resolution for deeply seated lesions of up to 3-4 cm. The ability to image early angiogenesis changes as well as tumor hypoxia in the ovary with this non-invasive imaging modality would greatly enhance the care for women at risk for ovarian cancer. Data obtained from our ex vivo imaging of normal, abnormal and malignant ovarian tissue have demonstrated that there is a significantly different angiogenic formation when malignant cancers and abnormal ovarian tissues are compared to normal ovarian tissues. We have developed a prototype co- registered photoacoustic and US system, which allows us to validate the hypothesis that this new imaging device will improve the current clinical practice for non-invasive diagnosis of early stage ovarian cancers and ovarian abnormality and will guide surgical intervention of high-risk ovarian cancer patients. In this proposal, we will 1) develop a transvaginal photoacoustic/US probe and system suitable for in vivo dual-modality non-invasive detection and characterization of the ovary; 2) characterize normal, abnormal and cancerous ovarian tissue ex vivo by comparing imaging results with histopathology and microvessel density counts and distributions as well as average optical absorption; 3) evaluate the prototype probe for in vivo imaging of patients who are scheduled for prophylactic oophorectomy; 4) monitor a group of high-risk premenopausal women during their menstrual cycles to determine the cyclic changes in functional and morphological parameters that may differ from angiogenesis changes associated with the malignant process. Approximately 60 patients will be recruited for the ex vivo study in Aim 2, which will allow us to validate the initial sensitivity and specificity of the proposed technique. Approximately 40 patients will be recruited for the in vivo study in Aim 3, which will allow us to evaluate the technique and validate the ex vivo results. Approximately 20 to 25 premenopausal high- risk patients will be recruited for the in vivo study in Aim 4, which will allow us to assess the efficacy of this new technique within a premenopausal population. The successful completion of the project will provide a means to improve the current clinical practice: it will provide necessary technology to improve the ability to determine if a cancer is present and to avoid surgery in a substantial number of women.